Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 14/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 14/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568963 | 0.98 | TDP1 (0.59) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL4394729 | 0.95 | KEAP1 (0.55) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL382722 | 0.89 | TDP1 (0.49) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL2892710 | 0.86 | TDP1 (0.58) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL7418996 | 0.84 | TDP1 (0.61) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL6998989 | 0.84 | TDP1 (0.61) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL4565127 | 0.83 | TDP1 (0.44) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL20438644 | 0.82 | TDP1 (0.43) | KEAP1NFE2L2TDP1CA12CA1 | |
| SCHEMBL3020258 | 0.81 | TDP1 (0.81) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL11250194 | 0.81 | TDP1 (0.56) | KEAP1NFE2L2TDP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383378-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | claimed |
| EP-3383376-B1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2021-05-12 | — | — | EP | claimed |
| EP-3383376-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| EP-3383378-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| CN-108601753-A | Method for inhibiting conversion of choline to Trimethylamine (TMA) | 宝洁公司 | 2018-09-28 | — | — | CN | claimed |
| WO-2017095995-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| WO-2017095993-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| EP-3383378-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2008010000-A1 | MOLECULAR DENDRITIC TRANSPORTERS | NATIONAL CENTER FOR SCIENTIFIC RESEARCH (GR) | 2008-01-24 | — | — | WO | disclosed |
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | IPSEN PHARMA S.A.S. (FR) | 2005-07-14 | — | — | US | disclosed |
| EP-1465880-A1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003045926-A1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHE ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-06-05 | — | — | WO | disclosed |
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | SSTR3, SSTR1, SSTR5 | KEAP1 3587/4885NFE2L2 3077/4885TDP1 4177/4885 |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | HNMT, BHMT, PNMT | KEAP1 167/4885NFE2L2 2060/4885TDP1 4705/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | KEAP1 1765/4885NFE2L2 4164/4885TDP1 4498/4885 |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR5, SSTR3 | KEAP1 4343/4885NFE2L2 4010/4885TDP1 3676/4885 |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | CRAT, CPT1A, CPT1B | KEAP1 78/4885NFE2L2 1069/4885TDP1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.